脐带血干细胞移植后膀胱原位癌卡介苗的安全有效给药。
Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation.
作者信息
Magaribuchi Toshihiro, Akamatsu Shusuke, Kobayashi Takashi, Kawabata Hiroshi, Yamasaki Toshinari, Inoue Takahiro, Ogawa Osamu
机构信息
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
出版信息
Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12758. Epub 2017 Sep 25.
Although intravesical Bacillus Calmette-Guérin (BCG) instillation is the standard treatment for carcinoma in situ of the bladder, it is generally contraindicated in immunocompromised patients. Here we report the first case, to our knowledge, of BCG treatment for a bladder cancer patient who had received umbilical cord blood stem cell transplantation (UCBSCT). BCG can be given safely and effectively in select cases where reconstitution of the immune system has been achieved at least 2 years after UCBSCT.
虽然膀胱内灌注卡介苗（BCG）是膀胱原位癌的标准治疗方法，但在免疫功能低下的患者中通常是禁忌的。据我们所知，本文报告了首例接受脐带血干细胞移植（UCBSCT）的膀胱癌患者接受BCG治疗的病例。在UCBSCT后至少2年免疫系统已重建的特定病例中，可以安全有效地给予BCG。
Zotero 插件